FinTech Dev and Data
Stock Risk Measures for Sarepta Therapeutics Inc
A quantitative factor review, as of July 31, 2020.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: August 02, 2020
See how we arrive at an overall risk score of
for SRPT below.
SRPT Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Sarepta Therapeutics Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how SRPT stock compares to 2,000+ US-based stocks, and to
peers in the Health Technology sector and Biotechnology industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Sector and Industry
- Sector: Health Technology
- Industry: Biotechnology
- SIC Code: 2834
Shares and Float
- Shares Outstanding: 77,988,700
- Shares Trading: 74,081,700
- Percent Trading: 95.0 %
Earnings and Dividends
- Trailing 12-month earnings: -8.83
- Next earnings date: 2020-08-05
- Dividends in last 12 months: None
- Ex-dividend date: None
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 0.91 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $11,972,825,224 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $115,784,695 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): 3.72% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -5.75% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
SRPT stock risk
SAREPTA THERAPEUTICS INC stock beta
SRPT risk report
SRPT risk analysis
SAREPTA THERAPEUTICS INC credit risk
SRPT liquidity risk
SRPT systematic risk
SRPT specific risk
SAREPTA THERAPEUTICS INC volatility
SRPT financial ratio